Response to azacitidine and the TIM-3 inhibitor, sabatolimab, in MDS and CMML is associated with distinct immune and antigen-presentation states
Aonkon Dey, Neal Smith, Alice Tirard, Benjamin Arnold, Thomas Chan, Jennifer Lombardi-Story, Timothy Casson, Tanya T. Behnan, Sergio Aguilar-Fernandez, Amir T. Fathi, Gabriela S. Hobbs, Hanno Hock, Philip C. Amrein, Patrick Reeves, Max Jan, , Alexandra-Chloe Villani
This study identifies immune and antigen-presentation states associated with response to azacitidine and sabatolimab in MDS and CMML using single-cell RNA sequencing.
bioRxiv · Nov 5, 2026 · PreprintCancer Biology